Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …

INTRODUCTION:: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been
compared with chemotherapy as first-line therapies for patients with advanced non-small …

Results: Literature search yielded eight randomized phase 3 clinical trials comparing
gefitinib, erlotinib, or afatinib with chemotherapy as first-line therapy in patients with …

Methods: Literature search was performed using relevant keywords. Direct and indirect meta-
estimates were generated using log-linear mixed-effects models, with random effects for …

Results: Literature search yielded eight randomized phase 3 clinical trials comparing
gefitinib, erlotinib, or afatinib with chemotherapy as first-line therapy in patients with …

Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …

Methods Literature search was performed using relevant keywords. Direct and indirect meta-
estimates were generated using log-linear mixed-effects models, with random effects for …

Introduction Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non-small-cell lung …

Issue Date: 2014 Citation: Haaland, B., Tan, PS, De Castro Jr., G., Lopes, G.(2014). Meta-
analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR …

Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non-small-cell lung …